Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Head and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K’s effect is moderate.
著者Hoi-Lam NGAN, Peony Hiu Yan POON, Yu-Xiong SU, Jason Ying Kuen CHAN, Kwok-Wai LO, Chun Kit YEUNG, Yuchen LIU, Eileen WONG, Hui LI, Chin Wang LAU, Wenying PIAO, Vivian Wai Yan LUI
期刊名稱npj Genomic Medicine,npj Genomic Medicine
出版年份2020
月份4
日期20
卷號5
期次1
出版社Nature Publishing Group
文章號碼17
國際標準期刊號2056-7944
語言英式英語

上次更新時間 2020-15-10 於 00:26